CN Patent

CN101702878B — 可溶性差的药物的药物组合物

Assigned to F Hoffmann La Roche AG · Expires 2012-11-28 · 13y expired

What this patent protects

本发明涉及可溶性差的化合物的固体分散体，其通过共沉淀和热熔挤出而形成，导致了改善的稳定性和生物利用度。本发明还涉及用于制备这类固体分散体的热熔挤出方法。

USPTO Abstract

本发明涉及可溶性差的化合物的固体分散体，其通过共沉淀和热熔挤出而形成，导致了改善的稳定性和生物利用度。本发明还涉及用于制备这类固体分散体的热熔挤出方法。

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN101702878B
Jurisdiction: CN
Classification: —
Expires: 2012-11-28
Drug substance claim: No
Drug product claim: No
Assignee: F Hoffmann La Roche AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.